Video

Liver Resectability in Metastatic Colorectal Cancer

For High-Definition, Click

It is important to determine whether disease in the liver can be resected when assessing an individual with liver metastatic colorectal cancer (CRC), since this treatment option could result in clinical remission post-surgery, says Marwan Fakih, MD. Patients who will benefit the most from surgery are those who have an R0 resection, meaning all microscopic margins are negative. However, some patients with a positive microscopic margin may still benefit from surgery, adds Fakih.

The likelihood of disease resectability can be stratified into the following categories: clearly resectable disease, possibly resectable disease, and unresectable disease. Individuals with metastatic disease to the liver that are deemed unresectable have the option of aggressive chemotherapy that may allow them to undergo resection down the road, states Fakih.

There are known benefits in beginning chemotherapy as soon as possible for patients with bulky metastatic disease, which may be accomplished without undergoing primary tumor resection. Individuals that may be considered for primary tumor resection include those with symptomatic disease or individuals with low volume disease in the liver, yet a sizable tumor in the colon, notes Fakih.

Patients with metastatic colorectal cancer often present with an unresected primary tumor, also known as synchronous metastatic disease. There has been a lot of debate regarding whether to resect the primary tumor, and clinical trials are ongoing that will help to answer this question. There is currently no clear evidence that this would improve overall survival, says Fakih.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Aparna Parikh, MD
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.